Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar; Natalie S. Callander; Kehinde Adekola; Larry D. Anderson; Muhamed Baljevic; Rachid Baz; Erica Campagnaro; Jorge J. Castillo; Caitlin Costello; Christopher D'Angelo; Benjamin Derman; Srinivas Devarakonda; Noura Elsedawy; Alfred Garfall; Kelly Godby; Jens Hillengass; Leona Holmberg; Myo Htut; Carol Ann Huff; Malin Hultcrantz; Yubin Kang; Sarah Larson; Hans Lee; Michaela Liedtke; Thomas Martin; James Omel; Timothy Robinson; Aaron Rosenberg; Douglas Sborov; Mark A. Schroeder; Daniel Sherbenou; Attaya Suvannasankha; Jason Valent; Asya Nina Varshavsky-Yanovsky; Jenna Snedeker; Rashmi Kumar

doi:10.6004/jnccn.2024.0001

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Christopher D'Angelo, Benjamin Derman, Srinivas Devarakonda, Noura Elsedawy, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin HultcrantzYubin Kang, Sarah Larson, Hans Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Jenna Snedeker, Rashmi Kumar

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

Original language	English (US)
Pages (from-to)	1-19
Number of pages	19
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	22
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2024.0001
State	Published - Jan 1 2024

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2024.0001

Cite this

Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., ... Kumar, R. (2024). Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22(1), 1-19. https://doi.org/10.6004/jnccn.2024.0001

Kumar, SK, Callander, NS, Adekola, K, Anderson, LD, Baljevic, M, Baz, R, Campagnaro, E, Castillo, JJ, Costello, C, D'Angelo, C, Derman, B, Devarakonda, S, Elsedawy, N, Garfall, A, Godby, K, Hillengass, J, Holmberg, L, Htut, M, Huff, CA, Hultcrantz, M, Kang, Y, Larson, S, Lee, H, Liedtke, M, Martin, T, Omel, J, Robinson, T, Rosenberg, A, Sborov, D, Schroeder, MA, Sherbenou, D, Suvannasankha, A, Valent, J, Varshavsky-Yanovsky, AN, Snedeker, J & Kumar, R 2024, 'Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 22, no. 1, pp. 1-19. https://doi.org/10.6004/jnccn.2024.0001

@article{2ff3192ae3fc4559888dd774e4cad429,

title = "Waldenstr{\"o}m Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology",

abstract = "The treatment of Waldenstr{\"o}m macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.",

author = "Kumar, {Shaji K.} and Callander, {Natalie S.} and Kehinde Adekola and Anderson, {Larry D.} and Muhamed Baljevic and Rachid Baz and Erica Campagnaro and Castillo, {Jorge J.} and Caitlin Costello and Christopher D'Angelo and Benjamin Derman and Srinivas Devarakonda and Noura Elsedawy and Alfred Garfall and Kelly Godby and Jens Hillengass and Leona Holmberg and Myo Htut and Huff, {Carol Ann} and Malin Hultcrantz and Yubin Kang and Sarah Larson and Hans Lee and Michaela Liedtke and Thomas Martin and James Omel and Timothy Robinson and Aaron Rosenberg and Douglas Sborov and Schroeder, {Mark A.} and Daniel Sherbenou and Attaya Suvannasankha and Jason Valent and Varshavsky-Yanovsky, {Asya Nina} and Jenna Snedeker and Rashmi Kumar",

year = "2024",

month = jan,

day = "1",

doi = "10.6004/jnccn.2024.0001",

language = "English (US)",

volume = "22",

pages = "1--19",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

TY - JOUR

T1 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

AU - Kumar, Shaji K.

AU - Callander, Natalie S.

AU - Adekola, Kehinde

AU - Anderson, Larry D.

AU - Baljevic, Muhamed

AU - Baz, Rachid

AU - Campagnaro, Erica

AU - Castillo, Jorge J.

AU - Costello, Caitlin

AU - D'Angelo, Christopher

AU - Derman, Benjamin

AU - Devarakonda, Srinivas

AU - Elsedawy, Noura

AU - Garfall, Alfred

AU - Godby, Kelly

AU - Hillengass, Jens

AU - Holmberg, Leona

AU - Htut, Myo

AU - Huff, Carol Ann

AU - Hultcrantz, Malin

AU - Kang, Yubin

AU - Larson, Sarah

AU - Lee, Hans

AU - Liedtke, Michaela

AU - Martin, Thomas

AU - Omel, James

AU - Robinson, Timothy

AU - Rosenberg, Aaron

AU - Sborov, Douglas

AU - Schroeder, Mark A.

AU - Sherbenou, Daniel

AU - Suvannasankha, Attaya

AU - Valent, Jason

AU - Varshavsky-Yanovsky, Asya Nina

AU - Snedeker, Jenna

AU - Kumar, Rashmi

PY - 2024/1/1

Y1 - 2024/1/1

N2 - The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

AB - The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

UR - http://www.scopus.com/inward/record.url?scp=85182866287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85182866287&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.0001

DO - 10.6004/jnccn.2024.0001

M3 - Article

C2 - 38244272

AN - SCOPUS:85182866287

SN - 1540-1405

VL - 22

SP - 1

EP - 19

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 1

ER -

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this